Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2009
At a glance
- Drugs Gimatecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 09 Jun 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 09 Jun 2009 Actual end date (Feb 2005) added as reported by ClinicalTrials.gov.
- 09 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.